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Abstract
Stroke is a leading cause of death in the United States. As ,60% of strokes result from carotid plaque rupture, elucidating
the mechanisms that underlie vulnerability is critical for therapeutic intervention. We tested the hypothesis that stable and
vulnerable human plaques differentially express genes associated with matrix degradation. Examination established that
femoral, and the distal region of carotid, plaques were histologically stable while the proximal carotid plaque regions were
vulnerable. Quantitative RT-PCR was used to compare expression of 22 genes among these tissues. Distal carotid and
femoral gene expression was not significantly different, permitting the distal carotid segments to be used as a paired
control for their corresponding proximal regions. Analysis of the paired plaques revealed differences in 16 genes that impact
plaque stability: matrix metalloproteinases (MMP, higher in vulnerable), MMP modulators (inhibitors: lower, activators:
higher in vulnerable), activating Fc receptors (FccR, higher in vulnerable) and FccR signaling molecules (higher in
vulnerable). Surprisingly, the relative expression of smooth muscle cell and macrophage markers in the three plaque types
was not significantly different, suggesting that macrophage distribution and/or activation state correlates with (in)stability.
Immunohistochemistry revealed that macrophages and smooth muscle cells localize to distinct and non-overlapping
regions in all plaques. MMP protein localized to macrophage-rich regions. In vitro, treatment of macrophages with immune
complexes, but not oxidized low density lipoprotein, C-reactive protein, or TNF-a, induced a gene expression profile similar
to that of the vulnerable plaques. That ligation of FccR recapitulates the pattern of gene expression in vulnerable plaques
suggests that the FccR R macrophage activation pathway may play a greater role in human plaque vulnerability than
previously appreciated.
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Introduction
The morbidity and mortality associated with stroke results from
the rupture of vulnerable carotid plaques; plaque removal by
carotid endarterectomy significantly decreases stroke risk[1]. In
contrast, femoral plaques are histologically and clinically stable,
with symptoms resulting from artery occlusion rather than plaque
embolism. As stabilizing vulnerable plaques represents a potential
therapeutic option, understanding the molecular differences
between stable and vulnerable plaques is essential for the design
of interventional therapies. Additionally, distinguishing patients
with plaques more susceptible to rupture from those that could be
managed medically would increase treatment choices for physi-
cians and patients.
A major factor contributing to plaque rupture is degradation of
the extracellular matrix. The matrix is predominantly collagen and
elastin[2], which can be degraded by matrix metalloproteinases
(MMP), specifically collagenase (MMP-1, 8), gelatinase (MMP-9)
and elastase (MMP-12). MMPs are proteases, secreted as inactive
precursors and activated by proteolytic cleavage, mainly by the
plasmin system. Plasmin is generated from plasminogen by
urokinase-type plasminogen activator (uPA). When bound to its
receptor, uPAR, uPA can produce plasmin for focal activation of
MMPs. The proteolytic activity of mature MMPs is regulated by
their association with tissue inhibitors of metalloproteinases
(TIMPs). Thus, the MMP:TIMP ratio determines overall MMP
activity [3].
Vulnerable plaques express elevated levels of MMP-1, MMP-8,
and MMP-9 that co-localize with activated macrophages[4].
Numerous plaque components activate macrophages, including
cytokines[5], oxidized LDL[5], C-reactive protein[6] (CRP), and
immune complexes[7] (IC). Despite the fact that IC are present in
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21803plaques and activate macrophages through Fcc receptor (FccR)
cross-linking, it is only now beginning to be recognized that IC can
influence plaque progression though FccR signaling. The
generation of atherosclerosis prone (ApoE-/- and LDLR-/-) FccR
-/- double knockout mice enabled the role for FccRi n
atherosclerosis to be studied in a mouse model. When fed a high
fat diet, plaque area is significantly higher in single vs double
knock-outs [8–9], implicating FccR in atherogenesis. However,
the link between FccR activation and plaque vulnerability in
humans is understudied. We postulate that plaque macrophages
take up IC and secrete MMPs for matrix degradation. Herein we
present evidence that vulnerable regions of human carotid plaques
have a pattern of gene expression significantly different from
paired proximal regions that are histologically stable. Additionally,
we demonstrate that engagement of macrophage FccRs with IC
induces a pattern of gene expression similar to that of the
vulnerable plaques, suggesting that FccR-activated macrophages
may play a greater role in plaque vulnerability than previously
appreciated.
Methods
Patient selection criteria
This investigation conforms to the principles outlined in the
Declaration of Helsinki. Specimens were procured and processed
according to approved IRB protocols. The study is classified as
exempt category 4; no informed consent was necessary. Femoral
and carotid endarterectomy tissue was provided by The Vascular
Group, PLLC based at Albany Medical Center. Femoral plaques
(n=14) were extracted by longitudinal arteriotomy, usually as an
adjunct to distal bypass; carotids (n=16) were removed using the
eversion method from symptomatic patients (3/16 or 19%) and
asymptomatic patients (13/16 or 81%) with .60% stenosis. Tissue
was collected sequentially over a 6-month period with the only
criteria for exclusion being absence of a morphologically distinct
distal and proximal segment, making it an inherently randomized
study.
Tissue Collection and Quantitative RT-PCR
Immediately upon removal, the tissue was placed in RNAlaterH
(Qiagen, Inc. Valencia, CA) and transported to the lab for
processing. Carotid plaques were divided into proximal (at, or
near, the carotid bifurcation) and distal (up the internal carotid
artery). From each carotid region, two contiguous blocks were
taken, one for paraffin embedding and one preserved in OCT
(optimal cutting temperature) for immunohistochemistry. RNA
was extracted from the remainder of the tissue. Proximal and distal
carotid and femoral tissue was weighed and RNA extracted with
Tri-reagent (Molecular Research Center, Cincinnati, OH).
Extraction was facilitated by homogenization with a Brinkman
PolytronH. cDNA was prepared from RNA using iScript (Bio-Rad,
Hercules, CA). qPCR primers (Table S1) were designed to amplify
100–200 bp fragments across an intron and were unique as
determined by BLAST analysis. Relative abundance of mRNA
was normalized to b-actin and calculated as 2
-(Ct gene – Ct actin)
where Ct represents the threshold cycle for each transcript. The
limits of detection were set at Ct $35. As the amount of RNA
recovered varied with the specimen, the genes were prioritized
(MMP, FccR.MMP activators, inhibitors, signaling genes). Thus,
the number of samples varies among the genes (n=8–16).
Histology
Paraffin-embedded tissue was sectioned (7 mm), stained with
Tri-chrome, and classified using the American Heart Association
stability criteria[2]. OCT-embedded tissue was cryosectioned
(7 mm) and mounted on Superfrost slides. Fixation (acetone,
10 min) and staining was done at room temperature. Sections
were blocked (45 min, PBS containing 1% Tween-20 and 10%
horse serum) and primary antibodies incubated for 1 h. Biotiny-
lated secondary antibodies (1:200, 1 h) were visualized using the
Vectastain ABC system (Vector Laboratories, Burlingame, CA).
Primary antibodies were mouse monoclonals (Table S2); isotype
controls (25 mg/ml) had no detectable staining. Immunohisto-
chemistry was done on 3–4 different proximal plaques. Despite
variations in plaque morphology (i.e., percent stenosis, eccentric-
ity, distribution of fibrous tissue), the localization of proteins with
respect to macrophages and smooth muscle cells was reproducible.
Zymography
Tissue lysates were prepared by homogenization and sonication
in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 12.7 mM
deoxycholate, 25 mM glycerophosphate, 1% SDS, and 1% Triton
X-100 containing protease inhibitors) followed by ultracentrifuga-
tion (1 h x 100,000 x g). 3 mg protein/well was run on 10% gelatin
gels according to manufacturers’ directions (Invitrogen, Carlsbad,
CA); 20 mg of HT15 media was used as the positive control [10].
Macrophage stimulation
Human monocytes, purified from peripheral blood by counter-
flow centrifugal elutriation, were purchased from The University
of Nebraska Medical Center. Elutriation separates the monocytes
from other blood cells based on their sedimentation in a
centrifugal field. The process uses physiological media, thus
maintaining cell viability and function. Monocytes were differen-
tiated (200 ng/ml recombinant human M-CSF, Cell Sciences,
Canton, MA) for 7 days. THP-1s, a human macrophage-like cell
line (ATCC #TIB-202), were differentiated with PMA (8.1 mM,
18 h) before use. Monocytes-derived macrophages (5610
6) and
Table 1. General characteristics of patient pool.
Endarterectomy site (n=30)
Characteristics
* Carotid Femoral p
Total 16 (53.3) 14 (46.7)
Age, (yrs) 67.869.1 65.868.7 .54
Male 10 (62.5) 10 (71.4) .71
Risk Factors
Hypertension 12 (75.0) 10 (71.4) 1.0
Hyperlipidemia 16 (100) 5 (35.7) ,.05
$
Diabetes 2 (12.5) 5 (35.7) .20
Cardiac Disease 9 (56.3) 8 (57.1) 1.0
Smoking 4 (25.0) 4 (28.6) 1.0
Symptomatic Carotid Disease 3 (18.8)
Asymptomatic Carotid Disease 13 (81.3)
Symptomatic Femoral Disease
Claudication 7 (50.0)
Rest Pain 2 (14.3)
Non-Healing Ulcer 4 (28.6)
Other 1 (7.1)
*Data are presented as mean 6 SD (%).
$ Statistically Significant.
doi:10.1371/journal.pone.0021803.t001
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6) were stimulated (18 h) with
200 ng/ml human TNF-a (Cell Sciences, Canton MA), 50 mg
protein/ml oxLDL (Invitrogen, Carlsbad, CA), 40 mg/ml C-
reactive protein (Calbiochem, San Diego, CA). The concentra-
tions used reflect serum concentrations in patients with athero-
sclerosis [6,11]. LDL was oxidized with 5 mM CuSO4 (20 h,
37uC); oxidation was confirmed using the TBARS assay with
malondialdehyde as the standard [12]. Average level of oxidation
was 18–23 nmol malondialdehyde equivalents/mg protein. Im-
mune complexes (IC) were presented as IgG-opsonized 2 mm
beads; 10 beads/cell reflecting standard phagocytosis ratios [13].
Following stimulation, RNA was extracted and qPCR performed
as above.
Statistical Analysis
The characteristics of the patient population were compared
using unpaired Student’s T-test and Fisher’s Exact Test. For the
gene analysis, the most appropriate statistical analyses were
performed. Specifically, as the tissue came from different patients,
gene expression in femoral and stable carotid specimens was
compared using an unpaired Student’s T-test. In contrast, the
vulnerable and stable carotid tissue came from the same plaque.
Thus, gene expression in these paired samples was compared using
a paired Student’s T-test. Within a gene, the tests were corrected
for multiple comparisons using Bonferroni’s correction and
significance accepted at the 0.05 level. For MMPs, uPA, and
uPAR, a logarithmic transformation was applied prior to
significance testing to correct for heteroscadisicity. As expected,
there is variability among the specimens. Although the extreme
outlyers may be due to unknown complications in the patient,
none were excluded. With a minimum of 8 patients, we estimate
that we would have adequate power (.80%) for detection of
differences between stable to vulnerable that are as large or larger
than 120% of within-group standard deviation.
Figure 1. Histology of human carotid and femoral plaques. (A) Carotid endarterectomy specimen with proximal (P) and distal (D) regions
indicated (bar =1 cm). Tri-chrome staining of the proximal (top, left) and distal (top, right) regions reveals necrotic cores with a thin cap
compromised by cellular infiltration (bottom, left) or protected by a thick fibrous cap (bottom, right), respectively. Bars =1 mm. (B) Femoral plaques
are characterized by an organized matrix (M) overlying a fibrocellular (FC) band deposited on a calcified (Ca) deposit. The lumen is designated with an
L. Bar =1 mm.
doi:10.1371/journal.pone.0021803.g001
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Full demographic details of the 30 patients in the study are
summarized in Table 1. No statistically significant differences were
found between the carotid and femoral patient pools with regards
to age, sex, hypertension, smoking, diabetes, and preexisting
coronary artery disease; hyperlipidemia was higher in carotid vs
femoral patient pools.
Stable plaques, regardless of anatomical location, have
similar gene expression patterns
To mitigate against stroke, carotid endarterectomy of asymp-
tomatic plaques with $60% stenosis is recommended[14,15,16].
Carotid endarterectomy specimens are often visually and hsitolo-
gically heterogeneous (Figure 1A). While a necrotic/lipid core is
present throughout, the core of the distal (relative to the heart)
region was relatively small and protected by a thick fibrous cap
while there was little or no cap overlying the proximal core
(Figure 1A). In contrast, proximal plaque regions exhibited
multiple histological indicators of instability (i.e., thin cap,
intraplaque hemorrhage, large necrotic core). This heterogeneity
is of considerable etiological interest. Is it possible that the fibrous
regions represent an earlier stage in plaque development, with
expansion of the fatty/necrotic core and activation of matrix
degradation a subsequent event leading to plaque vulnerability.
Alternatively, plaque histology may vary as a function of blood
flow, with that in the internal carotid (distal) more laminar and
that in the common carotid (proximal) being more disturbed. As
human specimens represent an endpoint in the disease process,
such etiological questions must be answered in animal models.
In contrast to their carotid counterparts, femoral plaques rarely
cause symptoms and thus are considered clinically stable, being
removed or bypassed to relieve lower limb ischemia. Trichrome
staining revealed that both femoral and distal carotid plaque tissue
was fibrocellular, with cells (red) embedded in an extensive
extracellular matrix (blue) (Figure 1, n=14 and 16, respectively).
Thus, we tested the hypothesis that their gene expression pattern
was similar. Of particular interest were genes for macrophages
(CD68) and smooth muscle cells (a-actin), matrix degradation
(MMPs, TIMPs, uPA, and uPAR), macrophage activation (FccRs,
TNF-a, MHC II, gp91
phox, PKC-d, iNOS), the inhibitory FccR
IIb, and the scavenger receptor for oxLDL (SR-A). A qRT-PCR
comparison between the femoral plaques and distal carotid plaque
regions revealed no significant differences in expression of 20/22
genes (Figure 2); only SR-A and uPAR were significantly different
(higher in femoral specimens).
SR-A is a scavenger receptor that internalizes oxLDL and
contributes to foam cell formation. That it was higher in femoral
plaques is intriguing as it suggests that elevated SR-A per se may not
predispose a plaque to rupture. As soluble oxLDL is taken up by
Figure 2. Expression levels for genes implicated in carotid
plaque vulnerability. Distal carotid plaque tissue and femoral tissue
have similar gene expression patterns; proximal and distal carotid tissue
have significantly different levels of these genes. The relative mRNA
expression for each gene for each plaque is represented by a single
point. For each gene and tissue, a Box plot is shown to the left of the
actual data. The Box plot indicates the median by a horizontal line
within the box; the top and bottom of the box represent the 75
th and
25
th percentile, respectively; the whiskers indicate the range of the data
and the dot indicates the mean. Statistical significance (p,0.05) is
indicated by an asterisk (*) for proximal vs. distal and by a dagger ({) for
femoral vs. distal. Expression was compared for femoral and distal
carotid specimens using an unpaired Student’s t-test.
doi:10.1371/journal.pone.0021803.g002
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plaques. The proximal (P) and distal (D) regions of a carotid plaque were stained with Trichrome to visualize fibrous tissue (blue) and cellular
material (red). Smooth muscle cells and macrophages were visualized by immunohistochemistry for a-actin (smooth muscle cells) and CD68
(macrophages). Smooth muscle cells co-localize with the fibrous material while macrophages localize to acellular areas.
doi:10.1371/journal.pone.0021803.g003
Figure 4. Relative gene expression in proximal vs distal plaque regions. A proximal/distal ratio was calculated from the qRT-PCR data
generated for each paired sample in Figure 2. Results are presented as mean 6 SEM (n=8–16). Genes with a ratio .1 are more highly expressed in
proximal tissue; ratios ,1 indicate a decrease in gene expression in the proximal vs distal regions. Genes are grouped by color according to function.
Statistical analysis and number of samples are presented in the accompanying table. Only genes that were significantly different (Figure 2) are
presented.
doi:10.1371/journal.pone.0021803.g004
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21803Figure 5. Matrix metalloproteinases localize to macrophages in proximal regions of carotid plaques. 7 mm cryosections were stained for
macrophages (CD68) or smooth muscle cells (a-actin) by immunohistochemistry. CD68 and a-actin localized to discrete regions of the plaque.
Sequential sections were stained for the indicated MMPs. MMP 8, 9, and 12 localized predominantly to the macrophages; MMP1 was present in both
smooth muscle cells and macrophages. L marks plaque lumen. Representative of three plaques giving similar results.
doi:10.1371/journal.pone.0021803.g005
Figure 6. Proximal regions of carotid plaques contain more MMP-9 than corresponding distal regions. Distal (D) and proximal (P)
regions were isolated from three carotid plaques and MMP9 levels were assessed by zymography using 3 mg of protein from each sample lysate.
Proximal regions contained more MMP-9 protein of both the pro and active forms, paralleling the mRNA expression (Figure 2) and consistent with
regulation of MMP-9 expression at the transcriptional level. +:20 mg of HT15 media was loaded as a positive control [10].
doi:10.1371/journal.pone.0021803.g006
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the uptake of oxLDL by a mechanism that doesn’t activate
macrophages. Indeed, neither PKC-d nor gp91
phox, genes involved
in the respiratory burst, were differentially expressed in femoral
tissue (Figure 2B). Thus, elevated SR-Alevelsmay be a physiological
response tothe increasedcirculating levelsofoxLDLinpatientswith
cardiovascular disease [18].
Most carotid plaques were visually heterogeneous, raising the
question as to the differences in the regions (Figure 1A). That the
distal region of carotid plaques had a gene expression pattern
similar to clinically stable femoral plaques, allowed us to use the
more powerful paired analysis to compare gene expression in the
proximal and distal portions of the same carotid plaque. As the
proximal portions of our carotid specimens had large necrotic
cores, thin or no fibrous caps, and evidence of hemociterin laden
foam cells (indicative of vulnerability), we predicted that they
would contain more macrophages. Surprisingly, there was no
significant difference in the expression of CD68 (macrophages)
and a-actin (smooth muscle cells) between proximal and distal
regions of carotid plaques (Figure 2). When stained for protein,
CD68 and a-actin did not overlap (Figure 3). Thus, the differences
in the amount of matrix (blue staining in Figure 1) could not be
explained by the separation of collagen-producing smooth muscle
cells from macrophages. Rather, the activation state of the
macrophage may account for the decreased matrix in the proximal
carotid plaques.
Gene expression in proximal regions favors matrix
degradation
When gene expression was compared between proximal and
distal regions of the same carotid plaque, 17 genes were differentially
expressed (Figure 4).
MMPs. Proximal carotid tissue had higher MMP-1, -8, -9 and
-12 mRNA expression compared to their corresponding distal
regions (Figures 2,4). Immunohistochemistry revealed that MMP-8,
-9 and -12 protein co-localized with macrophages in proximal
regions; MMP-1 was predominantly associated with smooth muscle
cells (Figure 5). Gelatin zymography was used to determine relative
levels of MMP-9 protein in stable and vulnerable tissue; Figure 6
presents the results of gelatin zymography on 3 different carotid
plaques. In all cases the proximal plaque regions contained more
MMP-9/unit protein when compared to the corresponding distal
segments. Thus, although not all MMP protein levels were
examined, the fact that 1) MMPs are constitutively secreted by
plaque macrophages [19], 2) they co-localized with macrophages
(Figure 5), and that 3) mRNA for multiple MMPs is elevated in
proximal carotid plaque tissue, is consistent with a model in which
macrophages in proximal carotid plaques release MMPs that
degrade the fibrous cap and destabilize the plaque. Although this
concept issupportedbypublishedstudies, this workisunique inthat
a comparison of gene expression has been done in stable and
vulnerable regions of the same carotid plaque and has been
combined with other markers of MMP regulation and macrophage
activation.
uPA and uPAR. The uPA/uPAR system processes MMPs to
their active forms. Accordingly, uPA and uPAR mRNA levels
were significantly higher in proximal regions (Figures 2, 4). The
combination of elevated uPA, uPAR, and MMPs favors MMP
activation and extracellular matrix breakdown.
Tissue inhibitors of metalloproteinases (TIMPs). TIMPs
bind to, and inhibit the activity of, mature MMPs. TIMP-2 and-3
mRNA were lower in proximal, compared to distal, regions
(Figures 2, 4). TIMP-2 protein was distributed throughout the
macrophage and smooth muscle cell regions while TIMP-3
localized to macrophages (Figure 7). Reduced TIMP-2 and-3
levels, combined with higher MMPs, would contribute to matrix
degradation. TIMP-1 message was significantly higher in proximal
vs distal regions (Figures 2, 4) and TIMP-1 protein localized to
macrophages (Figure 7). This is consistent with reports that TIMP-
1 overexpression does not alter plaque stability [20]. TIMP-4
mRNA was low and similar in both regions (Figure 2). This is not
surprising as TIMP 4 is predominantly expressed in cardiac tissue.
Taken together, our results suggest that, compared with their
distal counterparts, proximal carotid plaque regions contain higher
levels of active MMP-9 (lower band, Figure 6) and MMP
activating genes (uPA, uPAR, Figure 2). In these proximal regions,
reduced TIMP-2 and-3, combined with higher MMPs, would
favor matrix degradation (Figure 1), consistent with a phenotype
more likely to rupture.
Figure 7. Localization of tissue inhibitor of metalloproteinases (TIMPs) in proximal carotid plaque tissue. 7 mm cryosections of carotid
plaques were stained for macrophages (CD68) or smooth muscle cells (a-actin). Sequential sections were stained for the indicated TIMPs as described
in Methods. Isotype controls are presented in Figure 4. TIMPs 1 and 3 co-localized with macrophages; TIMP2 was expressed in both macrophages and
smooth muscle cells. Representative of three plaques giving similar results.
doi:10.1371/journal.pone.0021803.g007
FccR Signaling and Carotid Atherosclerosis
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21803Macrophages are activated in proximal regions of carotid
plaques
Several subtypes of macrophages have been described, activated
in different ways and expressing unique cadres of genes. Classically
activated macrophages (M1 subtype) are pro-inflammatory,
expressing elevated levels of FccRI, FccRIIa, FccRIII, TNF-a,
and releasing reactive oxygen species (ie, elevated NADPH
oxidase) [21,22]. In contrast, the M2 macrophages are immuno-
regulatory, with lower expression of FccRI, FccRIIa, FccRIII
(compared to M1), TNF-a, and reactive oxygen metabolites. As
MMPs associate with macrophages in the proximal plaque regions
(Figure 5), we evaluated the expression of genes associated with
macrophage activation, including FccRI, FccRIIa, FccRIII, TNF-
a, MHCII, PKC-d, and gp91
phox; PKC-d and gp91
phox were used
as indicators of elevated NADPH oxidase. With the exception of
MHCII, all of the genes were higher in proximal vs distal regions
(Figure 2). This gene expression pattern is consistent with the
presence of M1, classically activated macrophages [23] in the
proximal plaque tissue. With their elevated expression of activating
FccR, proximal plaque macrophages would be primed for pro-
inflammatory responses to immune complexes present in plaques.
In summary, the pattern of gene expression in proximal carotid
plaque regions is consistent with activated macrophages (higher
FccR, TNF-a, gp91
phox, PKC-d) and increased MMP activity (i.e.,
higher MMP, uPA, and uPAR expression and lower TIMP 2,3)
(Figure 4). These results define a cadre of genes, elevated in
proximal plaque tissue, that can cooperate to increase the level of
active MMPs, contributing to matrix degradation and increased
plaque vulnerability.
FccR ligation in macrophages recapitulates the gene
profile of proximal carotid plaques
Macrophages can be activated by many of the constituents of
plaques, notably TNF-a, oxLDL, C-reactive protein (CRP), and
immune complexes (IC). To assess the effects of macrophage
activation on the expression of the genes associated with vulnerable
Figure 8. TNF-a does not induce a vulnerable gene profile in macrophages. Differentiated THP-1 cells or monocyte-derived macrophages
were treated with 200 ng/ml human TNF-a for 18 h. RNA was extracted and subjected to qPCR. Data are presented as mean 6 SEM (normalized to b-
actin; n indicated in control column). Statistical significance compared by paired t-test for each replicate. * p,0.05, ** p,.01, *** p,.001. Yellow
boxes denote genes similarly regulated in proximal vs distal plaque tissue. Green and red numbers indicate significantly increased or decreased
expression, respectively compared to controls.
= Significance calculated from log values to compensate for heteroscedacity of the data.
doi:10.1371/journal.pone.0021803.g008
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macrophages were treated with TNF-a, oxLDL, CRP, or IC and
the resulting changes in gene expression were quantified. Of the 16
genes differentially expressed in proximal plaques (Figure 4),TNF-a
induced three in THP-1 cells and 7 in primary macrophages
(Figure 8). Of the MMPs detected in proximal plaques, only MMP-
9 was induced by TNF-a; TIMP levels were unaffected (Figure 8).
CRP did not alter the expression of any of the genes (data not
shown). Although oxLDL induced expression of 8 genes (Figure 9),
several genes involved in matrix degradation (eg, MMP-9, TIMP-1,
uPAR) were decreased, arguing against SR-A/oxLDL signaling as a
major contributor to matrix degradation. This finding is consistent
with our results demonstrating increased expression of SR-A
mRNA in femoral plaques. Although SR-A is increased, its ligation
with oxLDL may not induce MMP production and the plaques
remain fibrous.
Of the four compounds tested, IC induced a pattern of gene
expression most closely resembling that of proximal carotid plaque
tissue. Fifteen of the 16 genes were similarly regulated in IC-
treated THP-1 cells, 12 of 16 in primary macrophages (Figure 9).
Of particular relevance to plaque vulnerability is that IC up-
regulated the MMPs and down-regulated TIMPs 2 and 3. Thus,
IC, but not TNF-a, oxLDL, or CRP, induced a pattern of gene
expression in macrophages that recapitulates expression in
vulnerable regions of carotid plaques, consistent with a model in
which FccR-dependent signaling contributes to plaque vulnera-
bility.
If FccR ligation contributes to an inflammatory environment,
conditions that increase FccR expression and/or signaling would
be expected to be pro-atherosclerotic. Indeed, monocytes from
patients with acute coronary syndrome have significantly higher
FccR expression [24]. Also, individuals expressing the R131 allele
of FccR IIa have increased peripheral atherosclerosis compared to
those expressing H131[25]. Several other studies are consistent
with a model in which FccR signaling contributes to atheroscle-
rosis. First, lovastatin inhibits FccR-mediated phagocytosis[26].
Lower phagocytosis translates to less inflammation, a property of
the drug that may contribute to its’ atherosclerosis-reducing
effects. Secondly, the double TNF-a/Apo E knockout mouse has
decreased atherosclerosis when compared to the Apo E -/- single
knockout[27]. Thus, TNF-a, which is rapidly produced upon
FccR ligation, and is up-regulated in vulnerable carotid plaques
(Figures 2, 4), is pro-atherosclerotic. Finally, and most directly
relevant, Apo E-/- mice lacking FccRI and FccRIII, and
LDLR-/- mice deficient in FccRIII have significantly less
atherosclerosis than their Apo E/LDLR single knockout counter-
parts [8–9]. Conversely, deletion of the inhibitory FccR IIb in Apo
E-/- or LDLR -/- mice promotes atherosclerosis in the descending
Figure 9. Immune complexes recapitulate the gene expression pattern of vulnerable plaques. Differentiated THP-1 cells or monocyte-
derived macrophages were treated with immune complexes (10 beads/cell) or oxidized LDL (50 mg/ml). RNA was extracted and subjected to qPCR.
Data are presented as mean 6 SEM (normalized to b-actin; n indicated in control column). Statistical significance compared by paired t-test for each
replicate. * p,0.05, ** p,.01, *** p,.001. Yellow boxes denote genes similarly regulated in proximal vs distal plaque tissue. Green and red numbers
indicate significantly increased or decreased expression, respectively compared to controls.
= Significance calculated from log values to compensate
for heteroscedacity of the data.
doi:10.1371/journal.pone.0021803.g009
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mechanism by which activating FccR may contribute to matrix
degradation and plaque vulnerability.
Admittedly, as macrophages in the plaque milieu are exposed to
multiple stimuli this is an assessment focusing on the FccR R
MMP axis. Indeed, recent studies suggest that IC in conjunction
with toll-like receptor ligation, may generate a protective response
(review, [21]). However, the up-regulation of the activating FccR,
TNF-a, and gp91
phox suggest that the proximal carotid plaque
environment is conducive to M1 (inflammatory) macrophage
polarization. Laser capture microdissection will enable macro-
phages to be recovered from plaques. Expression profiling of such
macrophages will permit a comprehensive comparison of genes
differentially expressed in macrophages from vulnerable and stable
plaques and their comparison to the profile generated by
activation of macrophages through the FccR. However, the
results presented herein raise the intriguing possibility that FccR
ligation of plaque macrophages contributes to plaque instability, a
model that, to date, has received little attention.
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